🎯
LATEST VERIFIED ALGORITHMIC EXECUTION
Quantitative engine captured a net profit of +18.82% on $UPLD in just 17h 40m.
SYR
$SYRS
🔒 US EquitiesSyros Pharmaceuticals Inc
AVG HISTORICAL GAP
-0.62%
MAX GAP RECORD
-5.20%
🔒 PRO INSTITUTIONAL
AI PREDICTIVE WIN RATE
94.2%
REVEAL PRO DIRECTION ⚡
SENTINEL HISTORICAL GAP VIEWER
// $SYRS
📊 1-YEAR TIMELINE (GAPS PLOTTED)
🔮 SIMULATE SETUP 🔒
GAP INSPECTION // PLAYBACK PROTOCOL
$SYRS
HISTORICAL GAP OCCURRENCE
Analyzing price jump between T-1 close and opening auction.
EVENT DATE—
GAP MAGNITUDE—
T-1 CLOSE—
OPEN PRICE—
AI DIRECTIONPRO ONLY 🔒
Bullish Opening Gap
Bearish Opening Gap
T-1 Close Baseline
CATALYSTS & GAP HISTORY
| Oct 31, 2024 Earnings Release 2024-10-31 (BEFORE OPEN) |
+0.80%
|
| Jul 31, 2024 Earnings Release 2024-07-31 (BEFORE OPEN) |
+3.67%
|
| May 14, 2024 Earnings Release 2024-05-14 (BEFORE OPEN) |
+1.19%
|
| Mar 27, 2024 Earnings Release 2024-03-27 (BEFORE OPEN) |
-4.80%
|
| Nov 14, 2023 Earnings Release 2023-11-14 (BEFORE OPEN) |
-5.20%
|
| Aug 08, 2023 Earnings Release 2023-08-08 (BEFORE OPEN) |
-3.80%
|
| May 10, 2023 Earnings Release 2023-05-10 (BEFORE OPEN) |
+0.00%
|
| Mar 02, 2023 Earnings Release 2023-03-02 (BEFORE OPEN) |
+3.83%
|
VOLATILITY & GAP BIAS
AVG GAP MOVE
3.3%
Bullish Gaps (3)
Bearish Gaps (3)
Neutral / Flat (1)
📖 Intelligence Summary
Syros Pharmaceuticals, Inc. engages in the development of gene control therapies for cancer and diseases. Its product candidates include SY-1425, SY-2101, and SY-5609. The company was founded by Richard A. Young, Nathanael S. Gray, and James E. Bradner on November 9, 2011 and is headquartered in Cambridge, MA.
NEXT UPCOMING PREDICTIVE SIGNAL
STRONG BUY / TARGET +35%
🔓 REVEAL AI SIGNAL & TARGETS ↗